Your email has been successfully added to our mailing list.

×
0 0 -0.00373831775700943 -0.00373831775700943 -0.0205607476635515 -0.0355140186915889 -0.0355140186915889 -0.0355140186915889
Stock impact report

Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 [Seeking Alpha]

Neumora Therapeutics, Inc. (NMRA) 
Company Research Source: Seeking Alpha
Strong financial position with $171.5 million in cash, cash equivalents and marketable securities expected to support operations into 2027 More on Neumora Therapeutics Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs - Slideshow Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript Neumora to initiate phase 1 study of oral obesity pill Seeking Alpha's Quant Rating on Neumora Therapeutics Historical earnings data for Neumora Therapeutics Show less Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
NMRA alerts

from News Quantified
Opt-in for
NMRA alerts

from News Quantified